A comparison of salmeterol and formoterol in attenuating airway responses to short-acting β2-agonists

Pulmonary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2003, Pages 153-161

  Van Veen, A ^a   Weller, F R ^a   Wierenga, E A ^a   Jansen, H M ^a   Jonkers, R E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Asthma; Bronchoprotection; Formoterol; Partial antagonism; Salmeterol; Tolerance

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; FORMOTEROL; IPRATROPIUM BROMIDE; METHACHOLINE; PLACEBO; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0037998354     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-5539(03)00003-8     Document Type: Article

References (40)

1. www.ginasthma.com
2. Giannini D., Carletti A., Dente F.L., Bacci E., Di F.A., Vagaggini B., Paggiaro P.L. Tolerance to the protective effect of salmeterol on allergen challenge. Chest. 110:1996;1452-1457.
3. Cheung D., Timmers M.C., Zwinderman A.H., Bel E.H., Dijkman J.H., Sterk P.J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 327:1992;1198-1203.
4. Simons F.E., Gerstner T.V., Cheang M.S. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 99:1997;655-659.
5. Yates D.H., Kharitonov S.A., Barnes P.J. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med. 154:1996;1603-1607.
6. Bhagat R., Kalra S., Swystun V.A., Cockcroft D.W. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest. 108:1995;1235-1239.
7. Grove A., Lipworth B.J. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet. 346:1995;201-206.
8. Lipworth B.J., Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol. 103:1999;88-92.
9. Linden A., Bergendal A., Ullman A., Skoogh B.E., Lofdahl C.G. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax. 48:1993;547-553.
10. Blom M.W., Sommers K. Comparative pharmacology of salmeterol and formoterol and their interaction with salbutamol in healthy volunteers. Clin Drug Invest. 14:1997;400-404.
11. Rabe K.F., Jorres R., Nowak D., Behr N., Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 h in bronchial asthma. Am Rev Respir Dis. 147:1993;1436-1441.
12. Naline E., Zhang Y., Qian Y., Mairon N., Anderson G.P., Grandordy B., Advenier C. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J. 7:1994;914-920.
13. Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 160:1999;244-249.
14. Kallstrom B.L., Sjoberg J., Waldeck B. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol. 113:1994;687-692.
15. Molimard M., Naline E., Zhang Y., Le G.V., Begaud B., Advenier C. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J. 11:1998;583-588.
16. Sterk P.J., Fabbri L.M., Quanjer P.H., Cockcroft D.W., O'Byrne P.M., Anderson S.D., Juniper E.F., Malo J.L. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 16:1993;53-83.
17. Chai H., Farr R.S., Froehlich L.A., Mathison D.A., McLean J.A., Rosenthal R.R., Sheffer A.L., Spector S.L., Townley R.G. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol. 56:1975;323-327.
18. Jokic R., Davis E.E., Cockcroft D.W. Methacholine PC20 extrapolation (letter). Chest. 114:1998;1796-1797.
19. Newnham D.M., McDevitt D.G., Lipworth B.J. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma (see comments). Am J Med. 97:1994;29-37.
20. Booth H., Bish R., Walters J., Whitehead F., Walters E.H. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax. 51:1996;1100-1104.
21. Jones C.L., Cowan J.O., Flannery E.M., Hancox R.J., Herbison G.P., Taylor D.R. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J. 17:2001;368-373.
22. Beckett W.S., Marenberg M.E., Pace P.E. Repeated methacholine challenge produces tolerance in normal but not in asthmatic subjects. Chest. 102:1992;775-779.
23. Lipworth B., Tan S., Devlin M., Aiken T., Baker R., Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine (see comments). Am J Med. 104:1998;431-438.
24. McFadden E.R. Jr., Strauss L., Hejal R., Galan G., Dixon L. Comparison of two dosage regimens of albuterol in acute asthma. Am J Med. 105:1998;12-17.
25. Pan J.F., Yang P.C., Chang D.B., Yu C.J., Lee L.N., Kuo S.H. Nebulized fenoterol versus i.v. aminophylline treatment of acute severe asthma. Am J Emerg Med. 13:1995;677-680.
26. Rodrigo C., Rodrigo G. Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma. Chest. 113:1998;593-598.
27. Rodrigo G., Rodrigo C. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels. Am J Emerg Med. 14:1996;144-150.
28. Turner M.O., Patel A., Ginsburg S., FitzGerald J.M. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med. 157:1997;1736-1744.
29. Windom H.H., Burgess C.D., Crane J., Pearce N., Kwong T., Beasley R. The self-administration of inhaled beta agonist drugs during severe asthma. N Z Med J. 103:1990;205-207.
30. Lipworth B.J., Newnham D.M., Clark R.A., Dhillon D.P., Winter J.H., McDevitt D.G. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax. 50:1995;54-61.
31. Newhouse M.T., Dolovich M.B., Kazim F. Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma. Chest. 105:1994;1738-1742.
32. Green S.A., Turki J., Innis M., Liggett S.B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory. Biochemistry. 33:1994;9414-9419.
33. McGraw D.W., Forbes S.L., Kramer L.A., Liggett S.B. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 102:1998;1927-1932.
34. Parola A.L., Kobilka B.K. The peptide product of a 5′ leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 269:1994;4497-4505.
35. Scott M.G., Swan C., Wheatley A.P., Hall I.P. Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br J Pharmacol. 126:1999;841-844.
36. Drysdale C.M., McGraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan, Arnold K., Ruano G., Liggett S.B. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA. 97:2000;10483-10488.
37. Palmer L.J., Silverman E.S., Weiss S.T., Drazen J.M. Pharmacogenetics of asthma. Am J Respir Crit Care Med. 165:2002;861-866.
38. Taylor D.R., Hancox R.J., McRae W., Cowan J.O., Flannery E.M., McLachlan C.R., Herbison G.P. The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist. J Asthma. 37:2000;691-700.
39. Tan S., Hall I.P., Dewar J., Dow E., Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350:1997;995-999.
40. Israel E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M., Cooper D.M., Fahy J.V., Fish J.E., Ford J.G., Kraft M., Kunselman S., Lazarus S.C., Lemanske R.F., Martin R.J., McLean D.E., Peters S.P., Silverman E.K., Sorkness C.A., Szefler S.J., Weiss S.T., Yandava C.N., Nandabalan K. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 162:2000;75-80.